The IL-1 inhibitor Canakinumab for Familial Mediterranean Fever: the Greek experience in 12 patients

Abstract

Methods Twelve patients (7 men) with genetically confirmed FMF, fulfilling the Tel Hashomer criteria, aged 32.5 years (median, range 13-70), with median disease duration of 168 months and active disease refractory to colchicine (n=8) and/or anakinra (n=4), received Canakinumab 150mg subcutaneously every 4 (n=7) or 6 (n=3) or 8 weeks (n=2) for a median of 12… (More)

Topics

Cite this paper

@inproceedings{Laskari2015TheII, title={The IL-1 inhibitor Canakinumab for Familial Mediterranean Fever: the Greek experience in 12 patients}, author={Katerina Laskari and Panagiota Boura and Gn Dalekos and Alexandros A Garyfallos and Dimitrios Karokis and Dimitrios Pikazis and Loukas Settas and Grigorios Skarantavos and Elena Tsitsami and P. Sfikakis}, year={2015} }